Skip to main content
Premium Trial:

Request an Annual Quote

Galapagos Licenses Asthma and Allergy Targets, Provides Research to GSK

NEW YORK, Jan. 5 (GenomeWeb News) - Galapagos has licensed asthma and allergy drug targets to GlaxoSmithKline and will identify further targets for the drug maker, the Mechelen, Belgium-based company said today.


Under the agreement, GSK licensed a number of drug targets discovered by Galapagos using its siRNA-based adenovirus technology. In addition, Galapagos' reagents and services division, Galadeno, will use its SilenceSelect gene knock-down platform to discover and validate further targets for asthma and inflammatory diseases for GSK for three years.


GSK will pay Galapagos an upfront fee and provide research funding. Galapagos will also receive milestone payments for targets that GSK chooses to develop.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.